Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ME 344

Next Previous
Drug Profile

ME 344

Alternative Names: ME-344; NV-344

Latest Information Update: 06 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novogen
  • Developer MEI Pharma; Sarah Cannon Research Institute; Spanish National Cancer Research Centre; Tennessee Oncology
  • Class Antineoplastics; Isoflavones; Small molecules
  • Mechanism of Action Mitochondrial oxidative phosphorylation inhibitors; MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Cervical cancer; Colorectal cancer; HER2 negative breast cancer; Ovarian cancer; Small cell lung cancer

Most Recent Events

  • 06 Dec 2024 ME 344 is available for licensing as of 19 Sep 2024. https://meipharma.com/contacts.html
  • 06 Dec 2024 Discontinued - Phase-I for Colorectal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (IV)
  • 06 Dec 2024 Discontinued - Phase-I for HER2-negative-breast-cancer (Early-stage disease, First-line therapy, Combination therapy) in Spain (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top